ISCT 2022 San Francisco CMLE Approved Program Evaluation

Question Title

* 1. Contact Information

Name

Company

Address 1

Address 2

City/Town

State/Province

Zip/Postal Code

Country

Email Address

Question Title

* 2. Professional Category

MT(ASCP)

HT/HTL(ASCP)

MLT(ASCP)

PBT(ASCP)

CT(ASCP)

Other, please specify

Question Title

* 3. Professional Practice Category

Technologist

Research (pre-clinical)

Manager/Supervisor

Translational Development

Medical Director

QA/Regulatory

Other, please specify

Question Title

* 4. Years of Experience

0-1 Year

2-5 Years

6-10 Years

11+ Years

Question Title

* 5. Are you claiming credits for CMLE in California

Yes

Session Evaluations
Please complete the evaluation for all of the sessions you attended.
Refer to the Full Program for session times and titles here: Full Program

Question Title

* 6. Wednesday May 4 - 08:00-09:00 - CMLE Credit = 1
Roundtable Session Hour 1
Which of the following sessions did you attend?

Defining the Future of Cell Therapy Automation

CGT Workforce Development: Digging into the Problems and Root Causes of the Workforce Shortage Crisis

Global Market Strategies and Regulatory Considerations for Entering the APAC Market

Chain of Custody/Identity: Are there Broken Links to Fix that Ensure Patient Safety?

CAR T Infrastructure Expansion Beyond BMT Centers: How do we get there?

Navigating in the Dark: Off-Target Effects of Gene Editing

Optimizing the Vein to Vein Pathway

Mayo Clinic Building the Ecosystem in Regenerative Biotherapeutics

None of the above

Question Title

* 7. In the session you attended as indicated in Q 6, the speakers’ level of expertise regarding content presented was:

Excellent

Very Good

Good

Fair

Poor

N/A

Excellent

Very Good

Good

Fair

Poor

N/A

Question Title

* 8. Wednesday May 4 - 09:15-10:15 - CMLE Credit = 1
Roundtable Session Hour 2
Which of the following sessions did you attend?

Importance of utilizing multiparametric selection in isolating more persistent T cell population to enable better CAR-T therapy success

CGT Workforce Development: Managing the Revolving Door - Recruitment, Training, and Retention Strategies

Starting Materials: Donor Eligibility and Testing

Discussing the Complexity of Cold Chain Management

Current Approaches to Advanced Cell and Gene Therapies: How Much Risk is Too Much Risk?

Expectations and Challenges for iPSC-based Cell Therapies

Linking Patient Biology to MSC Responsiveness

Let’s Talk Particulates: Risk Assessment and Mitigation Practices for CGT Product Development

None of the above

Question Title

* 9. In the session you attended as indicated in Q 8, the speakers’ level of expertise regarding content presented was:

Excellent

Very Good

Good

Fair

Poor

N/A

Excellent

Very Good

Good

Fair

Poor

N/A

Question Title

* 10. Wednesday May 4 - 10:30-11:30 - CMLE Credit = 1
Roundtable Session Hour 3
Which of the following sessions did you attend?

Digitalization of Cell Therapy Laboratories

CGT Workforce Development: The Role of ISCT in the Creation of a Sustainable and Skilled Workforce

COVID-19 Effects on Critical Supply Shortages: Strategies to Adapt

Tackling Challenges in your Stability Program

Optimizing CAR T Therapies: Mitigating Toxicity While Improving Patient Outcomes

Debating the Acceptable Risk of AAV- Based Genomic Integration

Come to us First – Facilitating Product Development between Academia and Industry

Strategies to Attract Capital for CGT Tools and Technologies Businesses

None of the above

Question Title

* 11. In the session you attended as indicated in Q 10, the speakers’ level of expertise regarding content presented was:

Excellent

Very Good

Good

Fair

Poor

N/A

Excellent

Very Good

Good

Fair

Poor

N/A

Question Title

* 12. Wednesday May 4 - 13:00-14:00 - CMLE Credit = 1
Roundtable Session Hour 4
Which of the following sessions did you attend?

Creating an Academic-Industry Ecosystem for Advanced Therapies: The Cellicon Valley Story and Lessons Learned

Potency Assays: Why, When and What If?

Innovative Cell and Gene Therapy Clinical Trial Design and Development Strategies to Enhance Inclusivity and Diversity

Sterility testing: What and When to Test, and How to Manage Positive Results

CAR T Cell Therapy 10 Years Out: Are we at a Cure?

Debating the MSC paracrine MoA: EVs vs Efferocytosis

None of the above

Question Title

* 13. In the session you attended as indicated in Q 12, the speakers’ level of expertise regarding content presented was:

Excellent

Very Good

Good

Fair

Poor

N/A

Excellent

Very Good

Good

Fair

Poor

N/A

Question Title

* 14. Wednesday May 4 - 14:45-15:45 - CMLE Credit = 1
Roundtable Session
Did you attend the roundtable session "Expanded Access and Hospital Exemption: Understanding Investigational Treatment Pathways"?

Yes

Question Title

* 15. If you attended the session as indicated in Q 14, the speakers’ level of expertise regarding content presented was:

Excellent

Very Good

Good

Fair

Poor

N/A

Excellent

Very Good

Good

Fair

Poor

N/A

Question Title

* 16. Wednesday May 4 - 16:30-18:00 - CMLE Credit = 1.5
Did you attend the Presidential Plenary "Pioneering Gene Editing and Gene Modification for Patient Benefit Trailblazing New Paths in Designing Immunity"

Yes

Question Title

* 17. If you attended the presidential plenary, the speakers’ level of expertise regarding content presented was:

Excellent

Very Good

Good

Fair

Poor

N/A

Excellent

Very Good

Good

Fair

Poor

N/A

Question Title

* 1. Contact Information

Question Title

* 2. Professional Category

Question Title

* 3. Professional Practice Category

Question Title

* 4. Years of Experience

Question Title

* 5. Are you claiming credits for CMLE in California

Question Title

* 6. Wednesday May 4 - 08:00-09:00 - CMLE Credit = 1Roundtable Session Hour 1 Which of the following sessions did you attend?

Question Title

* 7. In the session you attended as indicated in Q 6, the speakers’ level of expertise regarding content presented was:

Question Title

* 8. Wednesday May 4 - 09:15-10:15 - CMLE Credit = 1Roundtable Session Hour 2Which of the following sessions did you attend?

Question Title

* 9. In the session you attended as indicated in Q 8, the speakers’ level of expertise regarding content presented was:

Question Title

* 10. Wednesday May 4 - 10:30-11:30 - CMLE Credit = 1Roundtable Session Hour 3Which of the following sessions did you attend?

Question Title

* 11. In the session you attended as indicated in Q 10, the speakers’ level of expertise regarding content presented was:

Question Title

* 12. Wednesday May 4 - 13:00-14:00 - CMLE Credit = 1Roundtable Session Hour 4Which of the following sessions did you attend?

Question Title

* 13. In the session you attended as indicated in Q 12, the speakers’ level of expertise regarding content presented was:

Question Title

* 14. Wednesday May 4 - 14:45-15:45 - CMLE Credit = 1Roundtable Session Did you attend the roundtable session "Expanded Access and Hospital Exemption: Understanding Investigational Treatment Pathways"?

Question Title

* 15. If you attended the session as indicated in Q 14, the speakers’ level of expertise regarding content presented was:

Question Title

* 16. Wednesday May 4 - 16:30-18:00 - CMLE Credit = 1.5Did you attend the Presidential Plenary "Pioneering Gene Editing and Gene Modification for Patient Benefit Trailblazing New Paths in Designing Immunity"

Question Title

* 17. If you attended the presidential plenary, the speakers’ level of expertise regarding content presented was:

Question Title

* 18. Total Credits on Wednesday

* 6. Wednesday May 4 - 08:00-09:00 - CMLE Credit = 1
Roundtable Session Hour 1
Which of the following sessions did you attend?

* 8. Wednesday May 4 - 09:15-10:15 - CMLE Credit = 1
Roundtable Session Hour 2
Which of the following sessions did you attend?

* 10. Wednesday May 4 - 10:30-11:30 - CMLE Credit = 1
Roundtable Session Hour 3
Which of the following sessions did you attend?

* 12. Wednesday May 4 - 13:00-14:00 - CMLE Credit = 1
Roundtable Session Hour 4
Which of the following sessions did you attend?

* 14. Wednesday May 4 - 14:45-15:45 - CMLE Credit = 1
Roundtable Session
Did you attend the roundtable session "Expanded Access and Hospital Exemption: Understanding Investigational Treatment Pathways"?

* 16. Wednesday May 4 - 16:30-18:00 - CMLE Credit = 1.5
Did you attend the Presidential Plenary "Pioneering Gene Editing and Gene Modification for Patient Benefit Trailblazing New Paths in Designing Immunity"